Putative tumor suppressor gene SEL1L was downregulated by aberrantly upregulated hsa-mir-155 in human pancreatic ductal adenocarcinoma

Molecular Carcinogenesis

Volumn 53, Issue 9, 2014, Pages 711-721

  Liu, Qian ^a   Chen, Jinyun ^a   Wang, Jin ^a   Amos, Christopher ^a   Killary, Ann M ^a   Sen, Subrata ^a   Wei, Chongjuan ^a   Frazier, Marsha L ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Gene expression regulation; Ingenuity Pathways Analysis; MicroRNA; Reverse phase protein assay

Indexed keywords

BETA CATENIN; CAVEOLIN 1; CLAUDIN 7; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; FIREFLY LUCIFERASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; KU80 PROTEIN; MICRO RNA 181A; MICRO RNA 181C; MICRORNA 143; MICRORNA 155; MICRORNA 205; MICRORNA 210; MICRORNA 223; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN; PROTEIN KINASE LKB1; PROTEIN SHC; RAD50 PROTEIN; SEL 1 LIKE PROTEIN; STAT3 PROTEIN; TAU PROTEIN; UNCLASSIFIED DRUG; V REL RETICULOENDOTHELIOSIS VIRAL ONCOGENE HOMOLOG A; VASCULOTROPIN RECEPTOR 2; LUCIFERASE; MESSENGER RNA; MICRORNA; MIRN155 MICRORNA, HUMAN; SEL1L PROTEIN, HUMAN; TUMOR MARKER;

ARTICLE; BINDING SITE; CELL DEATH; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; GENE OVEREXPRESSION; GENE REPRESSION; GENE TARGETING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMORTALIZED CELL LINE; LUCIFERASE ASSAY; MICROARRAY ANALYSIS; PANCREAS; PANCREAS ADENOCARCINOMA; PANCREATIC CANCER CELL LINE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR GENE; UPREGULATION; WESTERN BLOTTING; CELL CULTURE; DNA MICROARRAY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PANCREAS CARCINOMA; PANCREAS TUMOR; PATHOLOGY; PROTEIN MICROARRAY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

BLOTTING, WESTERN; CARCINOMA, PANCREATIC DUCTAL; CELLS, CULTURED; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUCIFERASES; MICRORNAS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PANCREAS; PANCREATIC NEOPLASMS; PROTEIN ARRAY ANALYSIS; PROTEINS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL;

EID: 84906258379     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.22023     Document Type: Article

References (39)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010; 60:277-300.
2. Cubilla AL, Fitzgerald PJ. Classification of pancreatic cancer (nonendocrine). Mayo Clin Proc 1979; 54:449-458.
3. Biunno I, Appierto V, Cattaneo M, et al. Isolation of a pancreas-specific gene located on human chromosome 14q31: Expression analysis in human pancreatic ductal carcinomas. Genomics 1997; 46:284-286.
4. Harada Y, Ozaki K, Suzuki M, et al. Complete cDNA sequence and genomic organization of a human pancreas-specific gene homologous to Caenorhabditis elegans sel-1. J Hum Genet 1999; 44:330-336.
5. Biunno I, Bernard L, Dear P, et al. SEL1L, the human homolog of C. elegans sel-1: Refined physical mapping, gene structure and identification of polymorphic markers. Hum Genet 2000; 106:227-235.
6. Grant B, Greenwald I. The Caenorhabditis elegans sel-1 gene, a negative regulator of lin-12 and glp-1, encodes a predicted extracellular protein. Genetics 1996; 143:237-247.
7. Grant B, Greenwald I. Structure, function, and expression of SEL-1, a negative regulator of LIN-12 and GLP-1 in C. elegans. Development 1997; 124:637-644.
8. Artavanis-Tsakonas S, Rand MD, Lake RJ. Notch signaling: Cell fate control and signal integration in development. Science 1999; 284:770-776.
9. Cattaneo M, Orlandini S, Beghelli S, et al. SEL1L expression in pancreatic adenocarcinoma parallels SMAD4 expression and delays tumor growth in vitro and in vivo. Oncogene 2003; 22:6359-6368.
10. Cattaneo M, Fontanella E, Canton C, Delia D, Biunno I. SEL1L affects human pancreatic cancer cell cycle and invasiveness through modulation of PTEN and genes related to cell-matrix interactions. Neoplasia 2005; 7:1030-1038.
11. Orlandi R, Cattaneo M, Troglio F, et al. SEL1L expression decreases breast tumor cell aggressiveness in vivo and in vitro. Cancer Res 2002; 62:567-574.
12. Larsen ZM, Angelo AD, Cattaneo M, et al. Complete mutation scanning of the human SEL1L gene: A candidate gene for type 1 diabetes. Acta Diabetol 2001; 38:191-192.
13. Eulalio A, Huntzinger E, Izaurralde E. Getting to the root of miRNA-mediated gene silencing. Cell 2008; 132:9-14.
14. Aleman LM, Doench J, Sharp PA. Comparison of siRNA-induced off-target RNA and protein effects. RNA 2007; 13:385-395.
15. Schickel R, Boyerinas B, Park SM, Peter ME. MicroRNAs: Key players in the immune system, differentiation, tumorigenesis and cell death. Oncogene 2008; 27:5959-5974.
16. Medina PP, Slack FJ. MicroRNAs and cancer: An overview. Cell Cycle 2008; 7:2485-2492.
17. Bloomston M, Frankel WL, Petrocca F, et al. MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis. JAMA 2007; 297:1901-1908.
18. Szafranska AE, Davison TS, John J, et al. MicroRNA expression alterations are linked to tumorigenesis and non-neoplastic processes in pancreatic ductal adenocarcinoma. Oncogene 2007; 26:4442-4452.
19. Lee EJ, Gusev Y, Jiang J, et al. Expression profiling identifies microRNA signature in pancreatic cancer. Int J Cancer 2007; 120:1046-1054.
20. Betel D, Wilson M, Gabow A, Marks DS, Sander C. The microRNA.org resource: Targets and expression. Nucleic Acids Res 2008; 36:D149-D153.
21. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001; 25:402-408.
22. Frazier ML, Pathak S, Wang ZW, et al. Establishment of a new human pancreatic adenocarcinoma cell line, MDAPanc-3. Pancreas 1990; 5:8-16.
23. Object-Oriented Microarray and Proteomic Analysis. Available from: http://bioinformatics.mdanderson.org/Software/OOMPA/
24. Ingenuity Pathways Analysis. Available from: http://www.ingenuity.com/
25. Greenbaum D, Colangelo C, Williams K, Gerstein M. Comparing protein abundance and mRNA expression levels on a genomic scale. Genome Biol 2003; 4:117.
26. Lee KM, Nguyen C, Ulrich AB, Pour PM, Ouellette MM. Immortalization with telomerase of the Nestin-positive cells of the human pancreas. Biochem Biophys Res Commun 2003; 301:1038-1044.
27. Grimson A, Farh KK, Johnston WK, Garrett-Engele P, Lim LP, Bartel DP. MicroRNA targeting specificity in mammals: Determinants beyond seed pairing. Mol Cell 2007; 27:91-105.
28. Krek A, Grun D, Poy MN, et al. Combinatorial microRNA target predictions. Nat Genet 2005; 37:495-500.
29. Velu CS, Baktula AM, Grimes HL. Gfi1 regulates miR-21 and miR-196b to control myelopoiesis. Blood 2009; 113:4720-4728.
30. Wu S, Huang S, Ding J, et al. Multiple microRNAs modulate p21Cip1/Waf1 expression by directly targeting its 3′ untranslated region. Oncogene 2010; 29:2302-2308.
31. Guo H, Ingolia NT, Weissman JS, Bartel DP. Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature 2010; 466:835-840.
32. Le MT, Shyh-Chang N, Khaw SL, et al. Conserved regulation of p53 network dosage by microRNA-125b occurs through evolving miRNA-target gene pairs. PLoS Genet 2011; 7:e1002242.
33. Larsson E, Sander C, Marks D. mRNA turnover rate limits siRNA and microRNA efficacy. Mol Syst Biol 2010; 6:433.
34. Tili E, Croce CM, Michaille JJ. miR-155: On the crosstalk between inflammation and cancer. Int Rev Immunol 2009; 28:264-284.
35. Faraoni I, Antonetti FR, Cardone J, Bonmassar E. miR-155 gene: A typical multifunctional microRNA. Biochim Biophys Acta 2009; 1792:497-505.
36. Chen X, Ba Y, Ma L, et al. Characterization of microRNAs in serum: A novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 2008; 18:997-1006.
37. Wang J, Chen J, Chang P, et al. MicroRNAs in plasma of pancreatic ductal adenocarcinoma patients as novel blood based biomarkers of disease. Cancer Prev Res 2009; 2:807-813.
38. Weiler J, Hunziker J, Hall J. Anti-miRNA oligonucleotides (AMOs): Ammunition to target miRNAs implicated in human disease? Gene Ther 2006; 13:496-502.
39. Wurdinger T, Costa FF. Molecular therapy in the microRNA era. Pharmacogenomics J 2007; 7:297-304.